Citations

Clear

141 citation(s) found for "Slack, S".

Glaucoma Progression and Development Following Secondary Intraocular Lens Surgery
Wang, Kenny Y. , Hassoun, Mohamad Rani , Sharma, Kannan

Mayo Clinic

Ophthalmic Surgery, Lasers and Imaging Retina | October 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-8

10.3928/23258160-20260819-03 | PMID 42823090 Get It

Background and Objective: This study aimed to investigate glaucoma progression following secondary intraocular lens (SIOL) implantation by surgical approach. Patients and Methods: This was a single-center retrospective study of 440 eyes that received SIOL implantation, including scleral-sutured, scleral-fixated, anterior chamber, and sulcus-fixated. Glaucoma progression was defined as new diagnosis, procedure for intraocular pressure (IOP) control, or IOP elevation ≥ 24 mmHg or ≥ 5 mmHg above baseline requiring additional medications. Risk factors were assessed using multivariable analysis. Results: Mean age at surgery was 71.3 years and 29.3% of patients had prior glaucoma. Overall, 33.2% developed glaucoma progression. Prior glaucoma (hazard ratio 2.08 [95% CI 1.47–2.94], P < .001) and cystoid macular edema (1.63 [1.06–2.52], P = .026) were associated with glaucoma progression on multivariable analysis. There was no difference in glaucoma progression between scleral-sutured, scleral-fixated, anterior chamber, or sulcus-fixated implantation techniques. Conclusion: Our results suggest that surgeons should use their preferred SIOL implantation technique but closely monitor postoperative IOP.
Assessing Electronic Health Record Use Burden Among Orthopedic Surgeons: A Single-Institution Study
Anderson, Megan L. , Hiredesai, Annika N., Zhuang, Joyce , Thornburg, Danielle A., Wallace, Alyssa K., Noland, Shelley S. , Anderson, Megan L. , Hiredesai, Annika N. , Thornburg, Danielle A.

Mayo Clinic

Orthopedics | September 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-8

10.3928/01477447-20260812-01 | PMID 42775936 Get It

Background: A growing body of research has connected electronic health record (EHR) workload to physician burnout. In orthopedic surgery, burn-out rates are rising. This study analyzed orthopedic surgeons' EHR use by sex and practice experience. Materials and Methods: EHR activity was analyzed among attending orthopedic surgeons at a single institution from May 2022 to May 2023. Demographic information included self-reported sex and practice years. Outcomes included time spent in notes, orders, clinical review, and in-basket daily; time spent outside of scheduled clinical responsibilities; volume of in-basket messages received daily; and proportion of orders with team contributions. Multivariable linear regression compared outcomes by sex and practice years. Results: A total of 105 orthopedic surgeons were included (91% male; mean 15.5 ± 9.8 practice years). Female surgeons logged 31% more time in the EHR overall (62.2 vs 47.4 minutes daily; P = .05) and on unscheduled days (10.1 additional daily minutes; P = .03), and received more messages from patients (2.4 vs 1.0 messages daily; P = .002) compared to male surgeons. Senior surgeons spent significantly less time on documentation and orders ( P ≤ .048) and on unscheduled days (3.3 less minutes daily per practice decade; P = .013), and had more support with placing orders ( P < .001). Conclusion: Female sex and fewer practice years were associated with increased EHR use. Female orthopedic surgeons tended to have higher patient message volumes, whereas junior surgeons tended to have less team support, spending more time on orders and documentation. Given known factors contributing to burnout, these findings warrant further investigation into targeted interventions to improve physician EHR use.
Gamification as an In Situ Educational Strategy for Nurses in the Clinical Setting
Gagliasso, Rachel M., Hinkle, Lacy J., Schammel, Andrea L., Stevens, Lauren R., Thurmes, Emma L., Rohwer, Bobbi Jo R., Gagliasso, Rachel

Mayo Clinic

The Journal of Continuing Education in Nursing | August 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.3928/00220124-20260615-02 | PMID 42600082 Get It

Background: Traditional educational methods often require protected time away from clinical duties, can be difficult to attend because of staffing or scheduling constraints, and may not consistently engage learners or meet individual learning needs. This article describes a gamified in situ microlearning approach to nursing professional development within the clinical practice setting that was designed to improve confidence and knowledge retention while maintaining staff satisfaction. Method: The educational intervention was provided in the clinical setting to avoid scheduling conflicts and interruptions in care. Results: Education on 18 topics was provided over 12 months. The gamified microlearning was associated with increased self-reported confidence without negatively impacting satisfaction. Conclusion: Gamified in situ microlearning can serve as a valuable adjunct to nursing professional development.
Risk‐Adjusted Comparison of Survival in Chronic Myelomonocytic Leukemia With and Without Allogeneic Stem Cell Transplant: Mayo Clinic Experience in 775 Consecutive Patients
Alsugair, Ali, Fathima, Saubia , Alhousani, Mohammad , Mariotti, E, Bolarinwa, Abiola , Faldu, Priyansh, Yousuf, Muhammad , Foran, James M. , Mangaonkar, Abhishek A. , Litzow, Mark, Sproat, Lisa, Palmer, Jeanne , Matin, Aasiya , Ayala, Ernesto , Slack, James L., Porrata, Luis, Khera, Nandita , Punwani, Nathan , Begna, Kebede H. , Pardanani, Animesh , Gangat, Naseema , Patnaik, Mrinal M. , Tefferi, Ayalew , Gauto‐Mariotti, Estefania , Alsugair, Ali , Alhousani, Mohammad M , Mariotti, Estefania Gauto , Csizmar, Clifford M. , Foran, James M , Mangaonkar, Abhishek A. , Litzow, Mark R. , Murthy, Hemant S , Matin, Aasiya , Ayala, Ernesto , Slack, James, Porrata, Luis , Iqbal, Madiha , Khera, Nandita , Kenderian, Saad Sirop , Chhabra, Saurabh , Pardanani, Animesh , Hogan, William J , Shah, Mithun V , Alkhateeb, Hassan B , Gangat, Naseema , Patnaik, Mrinal , Tefferi, Ayalew , Fathima, Saubia , Bolarinwa, Abiola B , Faldu, Priyansh, Murthy, Hemant S. , Iqbal, Madiha , Kenderian, Saad S. , Chhabra, Saurabh , Hogan, William J. , Shah, Meera , Alkhateeb, Hassan B.

Mayo Clinic

American Journal of Hematology | July 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajh.70453 | PMID 42499183 Get It

ABSTRACT The recently published BLAST clinical risk model for chronic myelomonocytic leukemia (CMML) and its molecular version (BLAST‐Mol) differentiate low, intermediate, and high‐risk groups. The objective of the current retrospective study was to examine the survival impact of allogeneic stem cell transplant (ASCT) in a consecutive series of Mayo Clinic patients ( n = 775; 68% males, median age 71 years) with CMML, overall and adjusted for baseline BLAST/BLAST‐Mol risk categories. At a median follow‐up of 77 months, 151 (20%) patients underwent ASCT. Overall survival (OS) was longer in the ASCT compared to the non‐ASCT cohorts (median 77 vs. 28 months; p < 0.01). The significant difference in OS between the ASCT and non‐ASCT cohorts was retained after adjusting for BLAST clinical risk groups: high‐risk (median 50 vs. 14 months; p < 0.01), intermediate‐risk (81 vs. 28 months; p < 0.01), and low‐risk (111 vs. 65 months; p = 0.04), respectively. The same was mostly the case when OS comparison was adjusted for BLAST‐Mol with respective p values of < 0.01, < 0.01, and 0.08, respectively. Time‐dependent cox models confirmed the favorable survival impact of ASCT in the BLAST/BLAST‐Mol high‐ and intermediate‐risk groups. The current study highlights the benefit of ASCT for BLAST/BLAST‐Mol high‐ and intermediate‐risk groups in CMML and its potential to overcome the adverse impact of some high risk cytogenetic or molecular abnormalities. These observations support the early use of ASCT in CMML, ideally before BT and regardless of genetic characteristics.
Visual Outcomes Following Cataract Surgery With Custom-Made Toric IOLs for the Correction of High Corneal Astigmatism
Reitblat, Olga , Dadon, Judith , Lejtman, Amit, Zlatkin, Rita , Cahn, Michal, Xia, Susan , Bahar, Irit , Sella, Ruti

Mayo Clinic

Journal of Refractive Surgery | July 10, 2026 | Volume: 42 | Issue: 7 | Pages: No page available

10.3928/1081597x-20260505-01 | PMID 42429247 Get It

Purpose: To describe the refractive results of cataract surgery in patients with high corneal astigmatism treated with implantation of custom-made toric intraocular lenses (IOLs). Methods: This retrospective cohort analysis of eyes implanted with high-cylinder (≥6.75 diopters [D]) custom-made toric IOLs was conducted at Rabin Medical Center, Petach Tikva, Israel. A control group of eyes implanted with standard toric IOLs (1.50 to 3.75 D) was also included. Postoperative IOL misalignment, uncorrected distance visual acuity (UDVA), residual refractive astigmatism (RA), and the prediction error (PE) of the toric IOL calculation using the Barrett Toric Calculator were assessed. Results: Twenty-two eyes of 22 patients were included. The mean ± standard deviation toric power was 9.67 ± 3.51 D (range: 6.75 to 19.00 D). Diagnoses included pellucid marginal degeneration (n = 7), keratoconus (n = 4), post-keratoplasty astigmatism (n = 3), and previous pterygium excision (n = 2). The mean postoperative UDVA was 0.28 ± 0.19 logarithm of the minimum angle of resolution (Snellen: 20/38). Mean absolute astigmatism decreased from 7.88 ± 3.15 D preoperatively (corneal) to 0.76 ± 0.87 D postoperatively (refractive) ( P < .001). One eye required redialing due to a 17° misalignment. Compared with the control group (41 eyes), the high-cylinder toric IOL group showed a slightly lower UDVA (20/30, P = .024) and a non-significant trend toward higher RA (0.58 ± 0.50, P = .930), as well as a significantly worse RA-PE, in both vector magnitude (1.47 vs. 0.62, P = .027) and vector dispersion (total bivariate variance 2.67 vs 0.40, px < 0.001 and py = 0.006). Conclusions: Customized high-cylinder toric IOLs significantly improve UDVA and reduce RA in eyes with extreme corneal astigmatism. Although slightly inferior to standard toric IOLs, they provide an effective treatment option for astigmatic correction in complex corneal pathologies with a central and relatively regular astigmatic component.
Caring for Transgender and Gender-diverse Parents
Kim, Hyun-Hee, Evangelinos, Eirini, Fonseca, Emrys , Cosner, Chelsea, Kim, Hyun-Hee , Cosner, Chelsea R.

Mayo Clinic

Psychiatric Annals | June 16, 2026 | Volume: 56 | Issue: 6 | Pages: No page available

10.3928/00485713-20260402-01 Get It

Transgender and gender-diverse (TGD) people comprise approximately 0.9% of adults in the United States; among them, 18% to 50% of TGD adults surveyed report being parents. Younger generations of Americans are more likely to identify as TGD, and also more likely to desire children than previous generations of TGD individuals surveyed. Despite this, TGD parents are often underrepresented in literature on parenting experiences of lesbian, gay, bisexual, transgender, and queer (LGBTQ+) parents. TGD parents experience significant mental health, physical health, and socioeconomic disparities due to gender minority stressors, and numerous barriers to reproductive care and affirming mental health care. This article presents an overview of the current literature on TGD parents, psychosocial outcomes for children of TGD parents, common clinical issues that may arise in treatment, and strategies for supporting TGD families to build resilience.
Clinical Characteristics and Outcomes of Hemorrhagic Choroidal Detachments From 2003–2020: A Single Center Experience
Wang, Kenny Y. , Xu, Timothy T. , Fortes, Blake H., Asheim, Collin G , Churchill, Robert A., Tailor, Prashant D. , Fortes, Blake H. , Starr, Matthew R.

Mayo Clinic

Ophthalmic Surgery, Lasers and Imaging Retina | June 11, 2026 | Volume: 57 | Issue: 6 | Pages: 350-354

10.3928/23258160-20260413-02 | PMID 42274717 Get It

Background and Objective: This study aimed to characterize clinical characteristics and visual outcomes of patients with hemorrhagic choroidal detachments. Patients and Methods: Single-center retrospective case series of patients with hemorrhagic choroidal detachments from January 1, 2003, to December 31, 2020 at Mayo Clinic. Patients were categorized as appositional or non-appositional based on ultra-sonography. Results: Among 39 cases with hemorrhagic choroidal detachments, 15 (38%) were appositional and 24 (62%) were non-appositional. There was a significant difference between the appositional and non-appositional groups in mean initial logMAR visual acuity (VA) (2.8 [ SD = 0.20] vs 2.2 [ SD = 0.78], P < .001). However, no difference was observed in final logMAR VA (1.9 [ SD = 1.2] vs 1.5 [ SD = 1.1], P = .30). Comparison between surgical ( N = 9) versus non-surgical ( N = 5) hemorrhagic appositional choroidal detachments cases revealed no differences in outcomes. Comparison between anticoagulated ( N = 21) versus nonanticoagulated ( N = 18) patients with hemorrhagic choroidal detachments also revealed no differences in outcomes. Conclusion: Patients with appositional and nonappositional hemorrhagic choroidal detachments did not differ significantly with regards to visual outcome. Surgical intervention was not associated with improved final vision in this cohort.
B22-01 Local Ancestral Loci Associated With Lung Function in African American Asthma Populations
Shrivastav, A, Slack, S, Zein, J G, Chiarella, S E, Althoff, M D, Daya, M, Cardet, J C, Hastie, A T, Hawkins, G A, Moore, W C, Barnes, K, Busse, W W, Castro, M, Denlinger, L C, Erzurum, S C, Jackson, D J, Jarjour, N N, Levy, I, Mauger, D, Szefler, S J, Israel, E, Wenzel, S E, Wechsler, M E, Bleecker, E R, Meyers, D A, Johnson, R K, Ortega, V E, Zein, Joe , Althoff, Meghan D. , Daya, Michelle , Cardet, Juan Carlos , Hastie, Annette T. , Denlinger, Loren C. , Szefler, SJ, Israel, Elliot , Wenzel, Sally E. , Wechsler, Michael E , Meyers, Deborah A. , Johnson, Rachel K.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.393 Get It

Abstract Rationale Higher African genetic ancestry has been associated with lower lung function, among individuals from specific racial-ethnic groups. The influence and interactions of genetic variation and ancestry in lung function is poorly understood. This study investigates ancestry-associated loci influencing lung function via admixture mapping and fine-scale allelic association. Methods 512 African American patients with asthma (≥12 years) from the Severe Asthma Research Program and Collaborative Study on the Genetics of Asthma (SARP/CSGA) cohorts were genotyped on the OmniExpress and HumanHap1M arrays or had whole-genome sequencing (WGS). For admixture mapping, global ancestry was inferred using ADMIXTURE and local ancestry estimated using RFMix v1.5.4 with CEU (N = 99) and YRI (N = 108) references across 15,095 local ancestry segments. Peak regions and contiguous segments (p &lt; 10-3) were fine mapped in SARP using local ancestry estimated from WGS with MAF ≥0.03. The Local Ancestry Adjusted Allelic Association (LAAA) model was used to fine map local genetic effect, local ancestry effect, and the interaction between the two, adjusted for age, sex, height, BMI, cohort, and percentage global African ancestry. SNPs with local genetic or interaction p &lt; 10⁻³ were tested for replication in 282 adolescent/adult participants from the Best African Response to Asthma Drugs (BARD) cohort genotyped with the MEGA array imputed to TOPMed (MAF ≥0.03). Results Mean African genetic ancestry was 81.3% in SARP and 80.1% in BARD. In SARP, African genetic ancestry was inversely associated with lung function (FEV₁:β = −7.9, p = 0.005; FVC:β = −9.0, p = 0.004), with stronger effects in females (FEV₁: β = −9.3, p = 0.003; FVC: β = −11.4, p = 0.001) than males (FEV₁:β = −6.4, p = 0.237; FVC:β = −5.7, p = 0.340). Similar total and sex-specific associations were identified in BARD. Admixture mapping in SARP/CSGA identified significant peaks for maximum FVC (p &lt; 1.87 × 10⁻4) on chromosomes 8 and 17 near RP1 and RBFOX3, and near-significant peaks on chromosome 5 near IQGAP2, SNRPCP2, SV2C and for the maximum FEV₁/FVC ratio on chromosome 10 near PCDH15. Fine mapping identified the top SNP on chromosome 8 (rs73587686; p-allele-dose=9.0x10-5; RGS20; q11.23), with 62 additional SNPs overlapping RGS20. SNP rs7825816 was also identified in SARP (β = 2.35, p-allele-dose =1.03 × 10⁻4) and replicated in BARD (β = 1.15, p-allele-dose =0.03). In BARD, LAAA also identified eight additional SNPs (p ≤ 0.05) in the same LD block (chr8:53914976-53918297) overlapping with RGS20, ATP6V1H, and TCEA1. Conclusions We identified multiple chromosomal regions associated with lung function in asthma patients of predominantly African genetic ancestry. Lung function associations were strongest at genetic variation near a key that was replicated in an independent asthma cohort. This abstract is funded by: R01 K08 HL118128, R01 HL142992, R01 NR013700, R01 HL69167, R01 HL161674, HL69116, HL69167, HL69170, HL69174, U10 HL109164, U10 HL109257, U10 HL109146, U10 HL109172, U10 HL109250, U10 HL109250, U10 HL109250, U10 HL109168, U10 HL109152, U10 HL109086-04, U10 HL098115, HL098102, HL098096, HL098075, HL098090, HL098177, HL098098, HL098107, HL098112, HL098103, and K12 HL89992
Hyperthyroidism, acromegaly, and hyperprolactinemia in a patient with a mature plurihormonal PIT-1 lineage adenoma
Carvalho, Julia Ferreira de , Slack, Daniel, Shrivastava, Raj, Richardson, Timothy E. , Levine, Alice C. , Ferreira de Carvalho, Julia , Yokoda, Raquel Teixeira, Levine, Alice C , Slack, Daniel, Yokoda, Raquel T.

Mayo Clinic

JCEM Case Reports | May 9, 2026 | Volume: 4 | Issue: 7 | Pages: No page available

10.1210/jcemcr/luag129 | PMID 42256640 Get It

Abstract Concurrent thyrotropin (TSH) secreting and growth hormone (GH) secreting pituitary adenomas are rare entities. Although tumors of the PIT-1 lineage may coexpress TSH and GH, concurrent biologically active secretion resulting in central hyperthyroidism and acromegaly is uncommon. We report the case of a 42-year-old woman presenting with weight loss, palpitations, amenorrhea, and progressive acromegalic features. Biochemical evaluation revealed central hyperthyroidism with elevated free T4 and inappropriately normal TSH, markedly elevated insulin-like growth factor 1 (IGF-1) and GH, hyperprolactinemia, and elevated α-subunit. Pituitary magnetic resonance imaging demonstrated a 2.7-cm macroadenoma with cavernous sinus extension. She underwent transsphenoidal resection without complications. Pathology confirmed a mature plurihormonal PIT-1 lineage adenoma immunopositive for TSH, GH, and prolactin with a Ki-67 of 3%. Immediately postoperatively, thyrotoxicosis and hyperprolactinemia resolved, IGF-1 levels declined, acromegalic features improved, and menses resumed. Over the ensuing months, thyroid and prolactin tests remained within normal range, but the IGF-1 level remained elevated. This case illustrates the rare presentation of a PIT-1 lineage adenoma secreting biologically active TSH, GH, and prolactin. Comprehensive hormonal evaluation and long-term biochemical and radiologic surveillance are essential, given the risk of incomplete remission despite apparent surgical cure.
Abstract 7903: MiR-362-3p enhances platinum response in breast cancer
Liu, Zhaoji, Ke, Shizhong, Li, Xiaohui, Wu, C., Uyemura, Madison M., Sardella, Barbara, Massicott, Erica S., Wang, Lin, Aronson, Emily K., Karagkouni, Dimitra, Kalavros, Nikolaos , Bogsan, Cristina S, Zhou, Lihan, Cheng, He, Garber, J. E., Schnitt, Stuart J. , Tung, Nadine M., Wulf, G. M., Heng, Yujing J., Ke, Shizhong, Li, Xiaohui, Wang, Lin , Aronson, Emily K., Karagkouni, Dimitra , Vlachos, Ioannis S. , Batalini, Felipe , Bogsan, Cristina Stewart Bittencourt , Cheong, Jit Kong , Cheng, He, Munson, Phillip B. , Mayer, Erica L. , Tung, Nadine , Kasinski, Andrea L. , Slack, Frank John , Wulf, Gerburg M. , Heng, Yujing J.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 7903-7903

10.1158/1538-7445.am2026-7903 Get It

Abstract The INFORM trial (NCT01670500) was a randomized, two-arm Phase II neoadjuvant study comparing the efficacy of a platinum-based regimen (cisplatin) versus an anthracycline (AC)-based regimen in participants with germline BRCA1/2 mutations and early-stage, HER2-negative breast cancer. MicroRNAs (miRNAs) are emerging as promising non-invasive biomarkers for disease detection and treatment monitoring. The initial aim of this study was to evaluate whether pretreatment plasma miRNA profiles were associated with treatment outcomes in the INFORM trial cohort. Pretreatment plasma samples from 97 INFORM participants (n=53 cisplatin and n=44 AC) were screened for 352 miRNAs commonly implicated in cancer using the qPCR-based ID3EALTM Cancer Panel. Twenty out of 53 participants achieved residual cancer burden (RCB) score of 0 or 1 with cisplatin and 20/44 with AC. Higher plasma miR-362-3p expression was associated with a favorable response to cisplatin (1.7-fold; p&lt;0.01), but not to AC. MiR-362-3p expression in paired pretreatment tumor biopsies (n=79) did not significantly correlate with plasma expression and was not associated with RCB 0/1 (p&gt;0.05). In TCGA, miR-362-3p expression was higher in breast tumors than in adjacent normal tissue, and higher in triple negative breast cancers (TNBCs) compared with hormone receptor-positive tumors (both FDR&lt;0.001), independent of BRCA mutation or Single Base Substitution Signature 3 (SBS3) status. The miR-362-3p findings in INFORM did not replicate in a sister trial, TBCRC 030 (NCT01982448; 11 out of 46 cisplatin-treated patients achieved RCB 0/1, p=0.46). These results suggest that while miR-362-3p is unsuitable as a circulating biomarker for cisplatin response, it may play an important biological role in mediating cisplatin sensitivity in TNBCs, independent of BRCA1/2 mutations. Functional studies demonstrated that miR-362-3p is expressed and secreted by TNBC cell lines, operates as a tumor suppressor, and generally correlates with cisplatin sensitivity. Overexpression of miR-362-3p rendered MDA-MB-231 and CAL-51 cells cisplatin sensitive, while knockdown induced resistance in MDA-MB-436 cells. Ongoing studies are testing whether these effects translate in xenograft models. In silico and functional assays identified BCLAF1, a DNA damage response (DDR) regulator, as a direct target of miR-362-3p. Overexpression of miR-362-3p suppresses BCLAF1 mRNA and protein levels. Our findings demonstrate that miR-362-3p enhances cisplatin responsiveness by targeting BCLAF1. A miR-362-3p-based therapeutic may be useful as a co-agent to enhance tumor responses to platinum-based chemotherapy. Citation Format: Zhaoji Liu, Shizhong Ke, Xiaohui Li, Catherine Wu, Madison M. Uyemura, Brian R. Sardella, Erica S. Massicott, Lin Wang, Emily K. Aronson, Dimitra Karagkouni, Nikolas Kalavros, Ioannis S. Vlachos, Felipe Batalini, Cristina S. Bogsan, Jit Kong Cheong, Lihan Zhou, He Cheng, Phillip Munson, Erica L. Mayer, Judy E. Garber, Stuart J. Schnitt, Nadine M. Tung, Andrea L. Kasinski, Frank J. Slack, Gerburg M. Wulf, Yujing J. Heng. MiR-362-3p enhances platinum response in breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7903.